Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.18    -0.005 (-2.70%)
Bid:
0.17
Ask:
0.19
Spread: 0.02 (11.765%)
Market Cap: £1.34m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Convertible Loan Note Offer

18 Jul 2006 15:48

Azure Holdings PLC18 July 2006 Azure Holdings plc (the "Company") Convertible Loan Note Offer The Company announces that it has today issued a letter to holders of ordinaryshares of 1p each in the Company ("Ordinary Shares"), on the share register ofthe Company on 17 July 2006, offering them the opportunity to participate in thesubscription of up to £1,200,000 nominal unsecured convertible loan stock 2008("Loan Stock"). The Loan Stock is being offered following discussions regarding a proposedacquisition by the Company ("Acquisition"). The proposed target for theAcquisition is ValiRX Limited ("ValiRX"), a biopharmaceutical developmentcompany. Discussions with ValiRX are progressing and the directors of theCompany hope to complete a reverse takeover under the AIM rules before 30September 2006. The principal terms of the Loan Stock are as follows: 1 Unless previously converted or repaid, the Loan Stock isrepayable 24 months from the date of the Loan Stock instrument under which it iscreated (the "Instrument") or at any time after 31 October 2006 at the Company'soption. 2 In partial consideration for the Loan Stock holderssubscribing for Loan Stock, a premium ("Premium") of £2 for each £1 nominal ofLoan Stock is payable, unless previously converted or paid, 24 months from thedate of the Instrument, or at any time after 31 October 2006 at the Company'soption. 3 Interest is payable from 1 November 2006 on the amount ofthe Loan Stock at the rate of two per cent. over the base rate of the Bank ofScotland plc from time to time. Interest is payable twice yearly. The firstinterest period will run from 1 November 2006 to 31 March 2007. 4 The conversion of Loan Stock ("Conversion") into OrdinaryShares is conditional upon approval by shareholders of resolutions to allotshares and disapply pre-emption rights; and if appropriate, the approval by avote of independent shareholders taken on a poll of any waiver granted by thePanel on Takeovers and Mergers of any obligation under rule 9 of the City Codeon Takeovers and Mergers which may arise from such Conversion (together the "Conversion Event") 5 Immediately prior to the Conversion Event, the Loan Stockis deemed repayable and the Premium is deemed payable. 6 On the Conversion Event, the Loan Stock and the Premiumwhich has not been repaid or paid as the case may be, will be converted intoOrdinary Shares in the capital of the Company at the rate of 100 Ordinary Sharesof the Company for each £1 otherwise due for repayment or payment. 7 So far as it is lawfully able to do so, the Company willnotify the Loan Stock holders at least 10 days in advance of the likelyoccurrence of the Conversion Event. 8 The Loan Stock is transferable in multiples of £10,000. 9 The Company is obliged to repay the Loan Stock and pay thePremium on the occurrence of certain events, including certain insolvencyevents. 10 Decisions relating to the Loan Stock are to be taken by a writtenresolution of the holders of at least two thirds in nominal value of theoutstanding Loan Stock. Applications for the Loan Stock may only be made for a minimum of £1,000 nominaland in multiples of £1,000. Applications for the Loan Stock are to be receivedby the Company at One Great Cumberland Place, London W1H 7AL by 3.00pm on 31July 2006. A copy of the letter despatched to shareholders and the Instrument are availablefor inspection, on request, at Halliwells LLP, 1 Threadneedle Street, LondonEC2R 8AW during normal business hours on any weekdays, Saturdays, Sundays andpublic holidays excluded, for one month from today. For further information, please contact: Barry Gold, Azure Holdings plcTel: 07768 948 928 David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Jan 20117:00 amRNSIssue of Equity
26th Jan 201110:58 amRNSResult of General Meeting
11th Jan 20117:00 amRNSPublication of Circular and Notice of GM
2nd Dec 20107:00 amRNSUpdate - Eurostars Programme
1st Dec 20107:00 amRNSTotal Voting Rights
10th Nov 20107:00 amRNSIssue of equity and update
1st Nov 20104:12 pmRNSTotal Voting Rights
29th Oct 20103:16 pmRNSIssue of Equity
29th Oct 20103:15 pmRNSChange of Adviser
11th Oct 201010:51 amRNSCompletion of Disposal
30th Sep 20102:17 pmRNSHalf Yearly Report
23rd Sep 20107:00 amRNSDisposal
31st Aug 20107:00 amRNSTotal Voting Rights
16th Aug 20105:12 pmRNSIssue of Equity
12th Aug 20107:00 amRNSLicensing Deal with Cancer Research Technology
15th Jul 20107:00 amRNSHPV Test Starts Clinical Validation
30th Jun 201010:15 amRNSResult of AGM
17th Jun 20107:00 amRNSEurostars' GeneICE Programme - First Year Review
17th Jun 20107:00 amRNSGeneICE Update
24th May 20107:00 amRNSRe Agreement
30th Apr 20102:47 pmRNSTotal Voting Rights
21st Apr 20104:08 pmRNSIssue of Equity - Replacement
21st Apr 20103:14 pmRNSResult of General Meeting
1st Apr 20103:19 pmRNSProposed reorg of share capital & Gen Meeting
1st Apr 201010:06 amRNSIssue of Equity
1st Apr 201010:06 amRNSTrading Update
31st Mar 20107:00 amRNSTotal Voting Rights
17th Mar 20107:00 amRNSSales and Distribution Agreement
15th Mar 201011:07 amRNSValiRx announces good stability data for VAL201
9th Mar 20107:00 amRNSFunding and Partnership Agreement
5th Mar 20103:00 pmRNSIssue of Equity
26th Feb 20104:30 pmRNSTotal Voting Rights
16th Feb 20109:00 amRNSIssue of Equity
29th Jan 201010:10 amRNSTotal Voting Rights
19th Jan 20107:00 amRNSGeneICE Update
13th Jan 20107:56 amRNSIssue of Equity
31st Dec 20098:03 amRNSIssue of Equity
30th Dec 20091:57 pmRNSResult of General Meeting
22nd Dec 200912:19 pmRNSRegional Funding
11th Dec 20097:42 amRNS?3m Equity Purchase Agreement
4th Dec 200910:14 amRNSNotice of General Meeting
25th Nov 20097:00 amRNSTrading Update
28th Sep 20097:40 amRNSHalf Yearly Report
14th Sep 20097:00 amRNSNew Distribution Venture & Trading Platform Launch
29th Jul 20098:06 amRNSAustralian Patent Acceptance
3rd Jul 200910:57 amRNSResult of AGM
10th Jun 20091:35 pmRNSFinal Results
10th Jun 20098:50 amRNSAward for cancer therapeutics project
29th May 20097:00 amRNSPlacing Summary and Total Voting Rights
11th May 20097:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.